| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7256310 | LUPIN | Levalbuterol salt |
Oct, 2024
(5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5362755 | LUPIN | Method for treating asthma using optically pure (R)-albuterol |
Mar, 2013
(11 years ago) | |
| US5547994 | LUPIN | Method for treating asthma using optically pure R(-) albuterol |
Aug, 2013
(10 years ago) | |
| US5605674 | LUPIN | Medicinal aerosol formulations |
Feb, 2014
(10 years ago) | |
| US5836299 | LUPIN | Seals for use in an aerosol delivery device |
Nov, 2015
(8 years ago) | |
| US8765153 | LUPIN | Levalbuterol salt |
Dec, 2023
(4 months ago) | |
Xopenex Hfa is owned by Lupin.
Xopenex Hfa contains Levalbuterol Tartrate.
Xopenex Hfa has a total of 6 drug patents out of which 5 drug patents have expired.
Expired drug patents of Xopenex Hfa are:
- US5362755
- US5547994
- US5605674
- US5836299
- US8765153
Xopenex Hfa was authorised for market use on 11 March, 2005.
Xopenex Hfa is available in aerosol, metered;inhalation dosage forms.
Xopenex Hfa can be used as treatment or prevention of bronchospasm or asthmatic symptoms.
The generics of Xopenex Hfa are possible to be released after 08 October, 2024.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-156) | Mar 12, 2018 |
Drugs and Companies using LEVALBUTEROL TARTRATE ingredient
Market Authorisation Date: 11 March, 2005
Treatment: Treatment or prevention of bronchospasm or asthmatic symptoms
Dosage: AEROSOL, METERED;INHALATION
XOPENEX HFA family patents
